©The Author(s) 2025.
World J Crit Care Med. Dec 9, 2025; 14(4): 103782
Published online Dec 9, 2025. doi: 10.5492/wjccm.v14.i4.103782
Published online Dec 9, 2025. doi: 10.5492/wjccm.v14.i4.103782
Table 1 Administration schedule
| Rounds | Route | Exosomes from Wharton’s Jelly-derived mesenchymal stem cells |
| Round 1 | IT | 30 × 109 exosomes in 3 mL |
| IM | 30 × 109 exosomes in 3 mL | |
| Round 2 (week 2) | IT | 30 × 109 exosomes in 3 mL |
| IM | 30 × 109 exosomes in 3 mL | |
| Round 3 (week 6) | IT | 30 × 109 exosomes in 3 mL |
| IM | 30 × 109 exosomes in 3 mL | |
| Round 4 (week 10) | IT | 30 × 109 exosomes in 3 mL |
| IM | 30 × 109 exosomes in 3 mL | |
| Round 5 (week 14) | IT | 30 × 109 exosomes in 3 mL |
| IM | 30 × 109 exosomes in 3 mL | |
| Round 6 (week 18) | IT | 30 × 109 exosomes in 3 mL |
| IM | 30 × 109 exosomes in 3 mL |
- Citation: Kabatas S, Civelek E, Savrunlu EC, Kaplan N, Akkoc T, Küçükçakır N, Bozkurt M, Karaöz E. Efficacy and safety of exosomes from Wharton’s Jelly-derived mesenchymal stem cells in traumatic brain injury. World J Crit Care Med 2025; 14(4): 103782
- URL: https://www.wjgnet.com/2220-3141/full/v14/i4/103782.htm
- DOI: https://dx.doi.org/10.5492/wjccm.v14.i4.103782